Search Results - "Ha, Belinda"

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results by Sax, Paul E., Tierney, Camlin, Collier, Ann C., Daar, Eric S., Mollan, Katie, Budhathoki, Chakra, Godfrey, Catherine, Jahed, Nasreen C., Myers, Laurie, Katzenstein, David, Farajallah, Awny, Rooney, James F., Ha, Belinda, Woodward, William C., Feinberg, Judith, Tashima, Karen, Murphy, Robert L., Fischl, Margaret A.

“…Background. AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or…”
Get full text

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study by Wohl, David A, Arnoczy, Gretchen, Fichtenbaum, Carl J, Campbell, Thomas, Taiwo, Babafemi, Hicks, Charles, McComsey, Grace A, Koletar, Susan, Sax, Paul, Tebas, Pablo, Ha, Belinda, Massengale, Kelly, Walsh, Kendall, Stein, James H

“…The association between abacavir (ABC) and cardiovascular disease (CVD) risk in HIV-infected individuals is unclear. Putative mechanisms for an effect of ABC…”
Get more information

Antiretroviral Exposure and Lymphocyte mtDNA Content Among Uninfected Infants of HIV-1-Infected Women by Aldrovandi, Grace M, Chu, Clara, Shearer, William T, Li, Daner, Walter, Jan, Thompson, Bruce, McIntosh, Kenneth, Foca, Marc, Meyer, William A., III, Ha, Belinda F, Rich, Kenneth C, Moye, Jack, Jr

“…Concern for potential adverse effects of antiretroviral (ARV) chemotherapy used to prevent mother-to-child HIV transmission has led the US Public Health…”
Get full text

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263) by Ross, Lisa, Elion, Richard, Lanier, Randall, Dejesus, Edwin, Cohen, Calvin, Redfield, Robert R, Gathe, Joseph C, Hsu, Ricky K, Yau, Linda, Paulsen, D, Ha, Belinda

“…COL40263 was a pilot 48-week, open-label, multicenter study evaluating the efficacy and safety of once-daily coformulated abacavir/lamivudine/zidovudine plus…”
Get more information

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 by McComsey, Grace A., Kitch, Douglas, Daar, Eric S., Tierney, Camlin, Jahed, Nasreen C., Tebas, Pablo, Myers, Laurie, Melbourne, Kathleen, Ha, Belinda, Sax, Paul E.

“…Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus…”
Get full text

Long-term body composition changes in antiretroviral-treated HIV-infected individuals by Grant, Philip M, Kitch, Douglas, McComsey, Grace A, Collier, Ann C, Bartali, Benedetta, Koletar, Susan L, Erlandson, Kristine M, Lake, Jordan E, Yin, Michael T, Melbourne, Kathy, Ha, Belinda, Brown, Todd T

“…OBJECTIVE:Body composition impacts physical function and mortality. We compared long-term body composition changes after antiretroviral therapy (ART)…”
Get full text

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy by Sax, Paul E, Tierney, Camlin, Collier, Ann C, Fischl, Margaret A, Mollan, Katie, Peeples, Lynne, Godfrey, Catherine, Jahed, Nasreen C, Myers, Laurie, Katzenstein, David, Farajallah, Awny, Rooney, James F, Ha, Belinda, Woodward, William C, Koletar, Susan L, Johnson, Victoria A, Geiseler, P. Jan, Daar, Eric S

“…In this prospective trial of fixed-dose, once-daily, nonnucleoside reverse-transcriptase inhibitors, patients with screening human immunodeficiency virus type…”
Get full text

Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus by Letendre, Scott L, Chen, Huichao, McKhann, Ashley, Roa, Jhoanna, Vecchio, Alyssa, Daar, Eric S, Berzins, Baiba, Hunt, Peter W, Marra, Christina M, Campbell, Thomas B, Coombs, Robert W, Ma, Qing, Swaminathan, Shobha, Macatangay, Bernard J C, Morse, Gene D, Miller, Thomas, Rusin, David, Greninger, Alexander L, Ha, Belinda, Alston-Smith, Beverly, Robertson, Kevin, Paul, Robert, Spudich, Serena

“…Abstract Background Neurocognitive impairment (NCI) in people with HIV (PWH) on antiretroviral therapy (ART) is common and may result from persistent HIV…”
Get full text

Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV by Letendre, Scott L, Chen, Huichao, McKhann, Ashley, Roa, Jhoanna, Vecchio, Alyssa, Daar, Eric S, Berzins, Baiba, Hunt, Peter W, Marra, Christina M, Campbell, Thomas B, Coombs, Robert W, Ma, Qing, Swaminathan, Shobha, Macatangay, Bernard J C, Morse, Gene D, Miller, Thomas, Rusin, David, Greninger, Alexander L, Ha, Belinda, Alston-Smith, Beverly, Robertson, Kevin, Paul, Robert, Spudich, Serena

“…Neurocognitive impairment (NCI) in people with HIV (PWH) on antiretroviral therapy (ART) is common and may result from persistent HIV replication in the…”
Get full text

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals by Grant, Philip M., Kitch, Douglas, McComsey, Grace A., Collier, Ann C., Koletar, Susan L., Erlandson, Kristine M., Yin, Michael T., Bartali, Benedetta, Ha, Belinda, Melbourne, Kathy, Brown, Todd T.

“…We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5…”
Get full text

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s by McComsey, Grace A., Kitch, Douglas, Sax, Paul E., Tebas, Pablo, Tierney, Camlin, Jahed, Nasreen C., Myers, Laurie, Melbourne, Kathleen, Ha, Belinda, Daar, Eric S.

“…Background. We compare the effect of 4 different antiretroviral regimens on limb and visceral fat. Methods. A5224s was a substudy of A5202, a trial of human…”
Get full text

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir by MCCOMSEY, Grace A, KITCH, Douglas, SAX, Paul E, DAAR, Eric S, TIERNEY, Camlin, JAHED, Nasreen C, MELBOURNE, Kathleen, HA, Belinda, BROWN, Todd T, BLOOM, Anthony, FEDARKO, Neal

“…The effect of specific antiretrovirals on inflammation is unclear. A5224s was a substudy of A5202, which randomized HIV-infected treatment-naïve patients to…”
Get full text

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202 by McComsey, Grace A, Kitch, Douglas, Sax, Paul E, Tierney, Camlin, Jahed, Nasreen C, Melbourne, Kathleen, Ha, Belinda, Brown, Todd T, Bloom, Anthony, Fedarko, Neal, Daar, Eric S

“…The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear. A5202 randomized 1857 treatment-naive…”
Get full text

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density by ERLANDSON, Kristine M, KITCH, Douglas, TIERNEY, Camlin, SAX, Paul E, DAAR, Eric S, TEBAS, Pablo, MELBOURNE, Kathleen, HA, Belinda, JAHED, Nasreen C, MCCOMSEY, Grace A

“…To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in…”
Get full text

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353 by Nyaku, Amesika N, Zheng, Lu, Gulick, Roy M, Olefsky, Maxine, Berzins, Baiba, Wallis, Carole L, Godfrey, Catherine, Sax, Paul E, Acosta, Edward P, Haas, David W, Smith, Kimberly Y, Sha, Beverly E, Van Dam, Cornelius N, Taiwo, Babafemi O

“…The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week…”
Get full text

Impact of randomized antiretroviral therapy initiation on glucose metabolism by Erlandson, Kristine Mace, Kitch, Douglas, Tierney, Camlin, Sax, Paul E, Daar, Eric S, Melbourne, Kathleen M, Ha, Belinda, McComsey, Grace A

“…OBJECTIVE:Prior studies have found that early HIV protease inhibitors contribute to glucose dysregulation. Few randomized trials have evaluated glucose indices…”
Get full text

A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial by Young, Benjamin, Vanig, Thanes, Dejesus, Edwin, Hawkins, Trevor, St Clair, Marty, Yau, Linda, Ha, Belinda, Shield Study Team

“…to evaluate raltegravir plus abacavir/lamivudine in antiretroviral-naïve, HIV-1-infected patients. SHIELD is an ongoing 96-week pilot study of…”
Get more information

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy by Taiwo, Babafemi O, Quiñones-Mateu, Miguel E, Smith, Kimberly, Zheng, Lu, Gulick, Roy, Nyaku, Amesika N, Sax, Paul E, Ha, Belinda, Kumwenda, Johnstone, Olefsky, Maxine, Godfrey, Catherine, Wallis, Carole

Get more information

Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine by Wyatt, Christina M, Kitch, Douglas, Gupta, Samir K, Tierney, Camlin, Daar, Eric S, Sax, Paul E, Ha, Belinda, Melbourne, Kathleen, McComsey, Grace A

“…BACKGROUND:Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir…”
Get full text

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy by Young, Benjamin, Fransen, Signe, Greenberg, Kenneth S, Thomas, Amy, Martens, Sharon, St Clair, Marty, Petropoulos, Christos J, Ha, Belinda

“…We report the case of an integrase strand-transfer inhibitor (INI)-resistant and four-drug-class-resistant HIV-1 variant infecting an antiretroviral…”
Get more information